

Thomas J Cradick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6458151/publications.pdf>

Version: 2024-02-01

34
papers

7,342
citations

331259

21
h-index

414034

32
g-index

34
all docs

34
docs citations

34
times ranked

11681
citing authors

#	ARTICLE	IF	CITATIONS
1	Base Editors Flex Sights on Sickle-Cell Disease. CRISPR Journal, 2021, 4, 166-168.	1.4	0
2	InÂvivo genome editing at the albumin locus to treat methylmalonic acidemia. Molecular Therapy - Methods and Clinical Development, 2021, 23, 619-632.	1.8	10
3	Evaluation of Homology-Independent CRISPR-Cas9 Off-Target Assessment Methods. CRISPR Journal, 2020, 3, 440-453.	1.4	32
4	Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β^2 -globin locus. Blood, 2018, 131, 1960-1973.	0.6	156
5	Cellular Therapies: Gene Editing and Next-Gen CAR T Cells. , 2016, , 203-247.		1
6	The Neisseria meningitidis CRISPR-Cas9 System Enables Specific Genome Editing in Mammalian Cells. Molecular Therapy, 2016, 24, 645-654.	3.7	190
7	Streptococcus thermophilus CRISPR-Cas9 Systems Enable Specific Editing of the Human Genome. Molecular Therapy, 2016, 24, 636-644.	3.7	204
8	A Burden of Rare Variants Associated with Extremes of Gene Expression in Human Peripheral Blood. American Journal of Human Genetics, 2016, 98, 299-309.	2.6	84
9	Nuclease Target Site Selection for Maximizing On-target Activity and Minimizing Off-target Effects in Genome Editing. Molecular Therapy, 2016, 24, 475-487.	3.7	100
10	TALENs Facilitate Single-step Seamless SDF Correction of F508del CFTR in Airway Epithelial Submucosal Gland Cell-derived CF-iPSCs. Molecular Therapy - Nucleic Acids, 2016, 5, e273.	2.3	38
11	Crispr/Cas9- Mediated Genome Editing of Human CD34+ Cells Upregulate Fetal Hemoglobin to Clinically Relevant Levels in Single Cell-Derived Erythroid Colonies. Blood, 2016, 128, 3623-3623.	0.6	3
12	Re-Creating Hereditary Persistence of Fetal Hemoglobin (HPFH) to Treat Sickle Cell Disease (SCD) and β^2 -Thalassemia. Blood, 2016, 128, 4708-4708.	0.6	2
13	331. Development of Neisseria meningitidis CRISPR/Cas9 Systems for Efficient and Specific Genome Editing. Molecular Therapy, 2015, 23, S132-S133.	3.7	4
14	Gene Editing with Crispr-Cas9 for Treating Beta-Hemoglobinopathies. Blood, 2015, 126, 3376-3376.	0.6	4
15	Efficient fdCas9 Synthetic Endonuclease with Improved Specificity for Precise Genome Engineering. PLoS ONE, 2015, 10, e0133373.	1.1	46
16	COSMID: A Web-based Tool for Identifying and Validating CRISPR/Cas Off-target Sites. Molecular Therapy - Nucleic Acids, 2014, 3, e214.	2.3	315
17	CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. Nucleic Acids Research, 2014, 42, 7473-7485.	6.5	548
18	Designing and Testing the Activities of TAL Effector Nucleases. Methods in Molecular Biology, 2014, 1114, 203-219.	0.4	6

#	ARTICLE	IF	CITATIONS
19	SAPTA: a new design tool for improving TALE nuclease activity. <i>Nucleic Acids Research</i> , 2014, 42, e47-e47.	6.5	49
20	An online bioinformatics tool predicts zinc finger and TALE nuclease off-target cleavage. <i>Nucleic Acids Research</i> , 2014, 42, e42-e42.	6.5	109
21	TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity. <i>Nucleic Acids Research</i> , 2014, 42, 6762-6773.	6.5	165
22	Nanomedicine: Tiny Particles and Machines Give Huge Gains. <i>Annals of Biomedical Engineering</i> , 2014, 42, 243-259.	1.3	26
23	Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5 Δ 32 mutation confers resistance to HIV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 9591-9596.	3.3	296
24	High-Throughput Cellular Screening of Engineered Nuclease Activity Using the Single-Strand Annealing Assay and Luciferase Reporter. <i>Methods in Molecular Biology</i> , 2014, 1114, 339-352.	0.4	13
25	Identification of Off-Target Cleavage Sites of Zinc Finger Nucleases and TAL Effector Nucleases Using Predictive Models. <i>Methods in Molecular Biology</i> , 2014, 1114, 371-383.	0.4	5
26	Codon Swapping of Zinc Finger Nucleases Confers Expression in Primary Cells and In Vivo from a Single Lentiviral Vector. <i>Current Gene Therapy</i> , 2014, 14, 365-376.	0.9	8
27	DNA targeting specificity of RNA-guided Cas9 nucleases. <i>Nature Biotechnology</i> , 2013, 31, 827-832.	9.4	3,953
28	CRISPR/Cas9 systems targeting β -globin and CCR5 genes have substantial off-target activity. <i>Nucleic Acids Research</i> , 2013, 41, 9584-9592.	6.5	544
29	Engineered zinc finger nucleases induce homology-directed repair with reduced mutagenic effects. <i>Nucleic Acids Research</i> , 2012, 40, 5560-5568.	6.5	160
30	Engineering imaging probes and molecular machines for nanomedicine. <i>Science China Life Sciences</i> , 2012, 55, 843-861.	2.3	13
31	ZFN-Site searches genomes for zinc finger nuclease target sites and off-target sites. <i>BMC Bioinformatics</i> , 2011, 12, 152.	1.2	38
32	Zinc-finger Nucleases as a Novel Therapeutic Strategy for Targeting Hepatitis B Virus DNAs. <i>Molecular Therapy</i> , 2010, 18, 947-954.	3.7	162
33	Controlling gene expression in <i>Drosophila</i> using engineered zinc finger protein transcription factors. <i>Biochemical and Biophysical Research Communications</i> , 2006, 348, 873-879.	1.0	7
34	Defining critical residues in the epitope for a hiv-neutralizing monoclonal antibody using phage display and peptide array technologies. <i>Gene</i> , 1993, 137, 63-68.	1.0	51